https://headachejournal.onlinelibrary.wiley.com/doi/abs/10.1111/head.13635
https://www.ncbi.nlm.nih.gov/pubmed/31508812?dopt=Abstract
Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?
Headache. 2019 Sep 11;:
Authors: Barbanti P, Egeo G, Mitsikostas DD
Abstract
Trigeminal-targeted treatments (TTTs), the most specific and selective therapeutic migraine approach to date, are effective in approximately 60% of patients regardless of treatment type or mechanism, at least if used alone. Sixty percent is also the proportion of migraineurs who develop migraine-like episodes following experimental intravenous administration of trigeminal neuropeptides and roughly 60% is the percentage of patients with a unilateral migraine tracing the area of cutaneous distribution of the trigeminal ophthalmic branch. Hence, mechanisms other than the trigeminovascular activation are probably involved in the 40% of migraineurs who do not respond to TTTs. A closer cooperation between clinical and basic neuroscientists is needed to explore migraine models because only a careful appraisal of migraine endophenotypes may help to unravel their underlying multifaceted pathophysiological machinery.
PMID: 31508812 [PubMed – as supplied by publisher]